Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI) CEO Deborah Rathjen sat down with Proactive’s Christine Corrado at BIO CEO & Investor Conference in New York. Rathjen explains how the revenue potential for brain metastasis of breast cancer is $404M. Bioasis has developed its proprietary brain delivery technology, the xB3 platform, to make drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose.
Bioasis Technologies says revenue potential for brain metastasis of breast cancer is $404M
Quick facts: Bioasis Technologies Inc.
Price: 0.3566 USD
Market Cap: $24.24 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE